Literature DB >> 1444378

Stabilization of botulinum toxin type A during lyophilization.

M C Goodnough1, E A Johnson.   

Abstract

Botulinum toxin for medical use is diluted to very low concentrations (nanograms per milliliter); when it is preserved by lyophilization, considerable loss of activity can occur. In the present study, conditions that gave > 90% recovery of the toxicity after lyophilization of solutions containing 20 to 1,000 mouse 50% lethal doses per ml were found. Toxicity was recovered upon drying 0.1 ml of toxin solution when the pH was maintained below 7 and bovine or human serum albumins were used as stabilizers. Various other substances tested with albumin, including glucose, sucrose, trehalose, mannitol, glycine, and cellibiose, did not increase recovery on drying.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444378      PMCID: PMC183118          DOI: 10.1128/aem.58.10.3426-3428.1992

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  7 in total

1.  Therapeutic use of type F botulinum toxin.

Authors:  C L Ludlow; M Hallett; K Rhew; R Cole; T Shimizu; G Sakaguchi; J A Bagley; G M Schulz; S G Yin; J Koda
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

Review 2.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

Review 3.  Interactions of stabilizing additives with proteins during freeze-thawing and freeze-drying.

Authors:  J F Carpenter; T Arakawa; J H Crowe
Journal:  Dev Biol Stand       Date:  1992

4.  Dose standardisation of botulinum toxin.

Authors:  N Quinn; M Hallett
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

5.  Statistical analysis of a rapid in vivo method for the titration of the toxin of Clostridium botulinum.

Authors:  D A Boroff; U Fleck
Journal:  J Bacteriol       Date:  1966-11       Impact factor: 3.490

6.  Double-blind study of botulinum toxin in spasmodic torticollis.

Authors:  J K Tsui; A Eisen; A J Stoessl; S Calne; D B Calne
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

7.  Distant effects of local injection of botulinum toxin.

Authors:  D J Lange; M F Brin; C L Warner; S Fahn; R E Lovelace
Journal:  Muscle Nerve       Date:  1987 Jul-Aug       Impact factor: 3.217

  7 in total
  5 in total

1.  Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Authors:  Hideyuki Arimitsu; Kaoru Inoue; Yoshihiko Sakaguchi; Jaechul Lee; Yukako Fujinaga; Toshihiro Watanabe; Tohru Ohyama; Robert Hirst; Keiji Oguma
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 2.  Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.

Authors:  David P Figgitt; Stuart Noble
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2010

4.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

5.  The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II.

Authors:  Mark S Nestor; David Arnold; Daniel Fischer
Journal:  J Cosmet Dermatol       Date:  2020-09-16       Impact factor: 2.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.